PDCD1 and colorectal carcinoma: Furthermore, in vivo MSI-high and microsatellite-stable (MSS) humanized CRC PDXs have been successfully established [164], and, as expected, characterization of these models confirmed higher levels of immune infiltrates and improved response to the PD-1 inhibitor, nivolumab, in MSI-high PDX models compared to MSS PDX models.